

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-22-5299	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The pharmacokinetic data in particular will be shared, and we found that the results of mouse liver targeting experiments were identical to those of in vivo imaging of small animals (2D and 3D), further indicating that GPs can be used as a vehicle for ABZ to achieve targeted treatment of hepatic echinococcosis.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One year within the publication date, since the technique or survival data may be updated over time.
7	To whom will you share the data?	Investigators and clinicians who are interested in studies of anti-hydatid drugs and β -1,3-D-glucan.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy of albendazole glucan nanoparticles in patients with echinococcosis.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: yanghaishan9558@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.